Company intelligence / Profile preview

TechVision

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

TechVision is a South Korean biotechnology company specializing in the development of next-generation adeno-associated virus (AAV) gene therapies for ophthalmic diseases. Founded by Dr. Jong-Mook Kim, the former CTO of ToolGen, the company leverages its proprietary AAV platform to optimize vector delivery and therapeutic expression in retinal cells. TechVision's lead candidate, TV-001, is an AAV-based gene therapy designed to treat Retinitis Pigmentosa by targeting mutations in the Rhodopsin (RHO) gene. The company is also advancing a pipeline of candidates for other inherited retinal dystrophies and common age-related conditions like Wet AMD.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyAAV
Industry: Biotech

Beyond the preview

Go deeper on TechVision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TechVision.

Explore the full profile